Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market

RANCHO CORDOVA, Calif., April 03, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the release of the X-Mini cell selection kit for the research market. The X-Mini isolates targeted cell subsets from blood and blood products, and is the first of several off-the-shelf kits that Cesca’s device subsidiary, ThermoGenesis, is developing for the research and development of CAR-T and other cell-based therapies.         

“The release of X-Mini represents a significant milestone for Cesca, as it signifies the initial launch of our proprietary CAR-TXpress platform,” said Chris Xu, chief executive officer of Cesca. “The X-Mini provides tangible advantages to research laboratories through a unique combination of attributes, including ease of use, high cell recovery and reproducibility, and minimal cost. During 2018, we look forward to the release of additional kits, including the X-Auto™ for non-commercial manufacturing of CAR-T cells as well as the X-Clini™, our first kit for Current Good Manufacturing Practice (cGMP)-compliant commercial manufacturing. The need for such products is strong, and we believe that our X-Series™ kits have the potential to revolutionize the rapidly evolving field of CAR-T therapy development and manufacturing.”      
     
The first X-Mini selection kit is designed for the isolation of CD3+ T cells from a starting population of peripheral blood mononuclear cells (PBMCs), but provides the flexibility to allow users to select any cell population for which they have a primary antibody.

About Cesca Therapeutics Inc.        
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected] 

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]